301 related articles for article (PubMed ID: 29362727)
21. Immune checkpoint inhibitor-induced isolated adrenocorticotropic hormone deficiency: a systematic review.
Wang F; Shi X; Yu X; Yang Y
Front Endocrinol (Lausanne); 2024; 15():1326684. PubMed ID: 38318292
[TBL] [Abstract][Full Text] [Related]
22. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR;
Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383
[TBL] [Abstract][Full Text] [Related]
23. Pituitary-related immune adverse events induced by programmed death Protein-1 inhibitors differ clinically from hypophysitis.
Yang L; Zhang Y; Chen X; Liu K; Zhou Y; Wang S
Clin Endocrinol (Oxf); 2024 May; ():. PubMed ID: 38753540
[TBL] [Abstract][Full Text] [Related]
24. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
25. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.
Zhao C; Tella SH; Del Rivero J; Kommalapati A; Ebenuwa I; Gulley J; Strauss J; Brownell I
J Clin Endocrinol Metab; 2018 Feb; 103(2):365-369. PubMed ID: 29220526
[TBL] [Abstract][Full Text] [Related]
26. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Seetharamu N; Preeshagul IR; Sullivan KM
Lung Cancer (Auckl); 2017; 8():67-78. PubMed ID: 28761384
[TBL] [Abstract][Full Text] [Related]
27. Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
Oğuz SH; Ünlütürk U; Aksoy S; Erbas T
Immunotherapy; 2021 Oct; 13(14):1157-1163. PubMed ID: 34387129
[TBL] [Abstract][Full Text] [Related]
28. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
[TBL] [Abstract][Full Text] [Related]
29. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Horn L; Gettinger SN; Gordon MS; Herbst RS; Gandhi L; Felip E; Sequist LV; Spigel DR; Antonia SJ; Balmanoukian A; Cassier PA; Liu B; Kowanetz M; O'Hear C; Fassò M; Grossman W; Sandler A; Soria JC
Eur J Cancer; 2018 Sep; 101():201-209. PubMed ID: 30077125
[TBL] [Abstract][Full Text] [Related]
30. Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report.
Li R; Jiang B; Zhu Y; Gao L; Zhou Y; Yang S
Endocr Metab Immune Disord Drug Targets; 2024; 24(5):606-610. PubMed ID: 37818555
[TBL] [Abstract][Full Text] [Related]
31. Iatrogenic Pituitary Shutdown: A Rare Adverse Event of Programmed Cell Death-Ligand 1 Inhibitor.
Al-Hiari M; Workman A; Ezeh E; Teka S
JCEM Case Rep; 2024 Jan; 2(1):luad157. PubMed ID: 38169902
[TBL] [Abstract][Full Text] [Related]
32. Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up.
Levy M; Abeillon J; Dalle S; Assaad S; Borson-Chazot F; Disse E; Raverot G; Cugnet-Anceau C
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33066179
[TBL] [Abstract][Full Text] [Related]
33. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
34. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
Fujita K; Uchida N; Yamamoto Y; Kanai O; Okamura M; Nakatani K; Sawai S; Mio T
Anticancer Res; 2019 Jul; 39(7):3917-3921. PubMed ID: 31262921
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy-Induced Anterior Hypophysitis.
Pachika PS; Khanam R; Faisal S; Ahmad T; Chandrasekhara Pillai A
Cureus; 2021 Jul; 13(7):e16538. PubMed ID: 34430146
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome.
Lanzolla G; Coppelli A; Cosottini M; Del Prato S; Marcocci C; Lupi I
J Endocr Soc; 2019 Feb; 3(2):496-503. PubMed ID: 30746508
[TBL] [Abstract][Full Text] [Related]
37. [Checkpoint inhibitors-induced hypophysitis].
du Payrat JA; Cugnet-Anceau C; Maillet D; Levy M; Raverot G; Disse E; Borson-Chazot F
Bull Cancer; 2020 Apr; 107(4):490-498. PubMed ID: 32200950
[TBL] [Abstract][Full Text] [Related]
38. Exploring a New Entity of Single-Agent Pembrolizumab-Associated Hypophysitis.
Balti E; Verhaeghe S; Kruse V; Roels S; Coremans P
Cureus; 2022 Aug; 14(8):e27763. PubMed ID: 36127991
[TBL] [Abstract][Full Text] [Related]
39. Diabetes insipidus: A rare endocrine complication of immune check point inhibitors: A case report and literature review.
Angelousi A; Papalexis P; Karampela A; Marra M; Misthos D; Ziogas D; Gogas H
Exp Ther Med; 2023 Jan; 25(1):10. PubMed ID: 36561623
[TBL] [Abstract][Full Text] [Related]
40. PD-1/PD-L1 inhibitors associated hypophysitis: An analysis from the FAERS database and case reports.
Chen S; Ouyang L; Li L; Xiao Y; Wang S
Drug Discov Ther; 2024 Mar; 18(1):34-43. PubMed ID: 38382932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
